Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma (NCT00002715) | Clinical Trial Compass
CompletedPhase 2
Combination Chemotherapy in Treating Patients With Advanced Hodgkin's Lymphoma
United States50 participantsStarted 1989-04
Plain-language summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced Hodgkin's lymphoma.
Who can participate
Age range18 Years – 60 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
DISEASE CHARACTERISTICS:
* Histologically confirmed Hodgkin's lymphoma of any histology
* Unfavorable disease required
* Clinical stage IIIA, IIIB, IV, or IIB (non-bulky)
* Locally extensive stage I or II with either of the following:
* Mediastinal mass greater than 1/3 the maximum intrathoracic diameter
* Two or more extranodal sites
PATIENT CHARACTERISTICS:
Age:
* 18 to 60
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Not specified
Other:
* No prior malignancy except nonmelanomatous skin cancer
* No significant concurrent illness that precludes protocol participation
PRIOR CONCURRENT THERAPY:
* No prior treatment for Hodgkin's lymphoma
Biologic therapy
* Not specified
Chemotherapy
* Not specified
Endocrine therapy
* Not specified
Radiotherapy
* Not specified
Surgery
* Not specified